Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 13, 2012, Pages 4377-4385

  Kumar, D Vijay ^a   Hoarau, Christophe ^a   Bursavich, Matthew ^a   Slattum, Paul ^a   Gerrish, David ^a   Yager, Kraig ^a   Saunders, Michael ^a   Shenderovich, Mark ^a   Roth, Bruce L ^a   McKinnon, Rena ^a   Chan, Ashley ^a   Cimbora, Daniel M ^a   Bradford, Chad ^a   Reeves, Leslie ^a   Patton, Scott ^a   Papac, Damon I ^a   Williams, Brandi L ^a   Carlson, Robert O ^a  

^a Myrexis Inc   (United States)

Author keywords

Cancer; Kinase selectivity; Lead optimization; Mps1 kinase; TTK kinase

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ENZYME; MPI 0479605; MPS 1 ENZYME; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CELL STRAIN HCT116; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; TUMOR XENOGRAFT;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; G2 PHASE CELL CYCLE CHECKPOINTS; HCT116 CELLS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MICE; MOLECULAR CONFORMATION; MORPHOLINES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862190104     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.04.131     Document Type: Article

References (17)

1. A. Musacchio, and E.D. Salmon Nat. Rev. Mol. Cell Bio. 8 2007 379
2. S.T. Liu, G.K. Chan, J.C. Hittle, G. Fujii, E. Lees, and T.J. Yen Mol. Biol. Cell 14 2003 1638
3. M. Malumbres Physiol. Rev. 91 3 2011 973
4. G. De Cárcer, I. Pérez de Castro, and M. Malumbres Curr. Med. Chem. 14 9 2007 969
5. M. Malumbres, and M. Barbacid Curr. Opin. Genet. Dev. 17 2007 60
6. J. Kang, and H. Yu J. Biol. Chem. 284 23 2009 15359
7. K.D. Tardiff, A. Roger, J. Cassiano, B.L. Roth, D.M. Cimbora, R. McKinnon, A. Peterson, T. Douce, R. Robinson, I. Dorweiler, T. Davis, M.A. Hess, K. Ostanin, D.I. Papac, V. Baichwal, I. McAlexander, J.A. Willardsen, M. Saunders, C. Hoarau, D.V. Kumar, D.A. Wettstein, R.O. Carlson, and B.L. Williams Mol. Cancer Ther. 10 2011 2267
8. S. Santaguida, A. Tighe, A.M. D'Alise, S.S. Taylor, and A. Muscchio J. Cell Biol. 190 2010 73
9. M. Caldarelli, M. Angiolini, T. Disingrini, D. Donati, M. Guanci, S. Nuvoloni, H. Posteri, F. Quartieri, M. Silvagni, and R. Colombo Bioorg. Med. Chem. Lett. 21 2011 4507
10. N. Kwiatkowski, N. Jelluma, P. Fillippakopouls, M. Soundararajan, M.S. Manak, M. Kwon, H.G. Choi, T. Sim, Q.L. Deveraux, S. Rottmann, D. Pellman, J.V. Shah, G.J.P.L. Kops, S. Knapp, and N.S. Gray Nat. Chem. Biol. 6 2010 359
11. L. Hewit, A. Tighe, S. Santaguida, A.M. White, C.D. Jones, A. Musacchio, S. Green, and S.S. Taylor J. Cell Biol. 190 2010 25
12. W. Lan, and D.W. Cleveland J. Cell Biol. 190 2010 21
13. J. Maciejowski, K.A. George, M.E. Terret, C. Zhang, K.M. Shokat, and P.V. Jallepalli J. Cell Biol. 190 2010 89
14. 6) solved with resolution 2.60 Å was used as a target for docking. Docking model of Mps1 complex with compound 1 was further refined using Schrodinger Induced Fit Docking protocol: Sherman, W.; Day, T.; Jacobson, M.P.; Friesner, R.A.; Farid, R.; J. Med. Chem., 2006, 49,534-553. The images were made with Accelrys Discovery Studio Visualizer, release 3.2, Accelrys Software Inc., San Diego, USA, 2011.
15. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Adv. Drug Deliv. Rev. 46 2001 3
16. Kumar, D. V.; McAlexander, I; Bursavich, M.; Hoarau, C.; Slattum, P.; Gerrish, D.; Lockman, J.; Judd, W.; Saunders, M.; Parker, D.;. Zigar, D.; Kim, I.; Willardsen, J.; Yager, K.; Shenderovich, M.; Williams, B.; Tardiff, K. WO 2010/111406.
17. G.A. Molandar, and C.S. Yun Tetrahedron 58 2002 1465